How much funding has Vir Biotechnology raised?

Vir Biotechnology has raised $250.0M in total funding, most recently a Growth Equity round.

Who are Vir Biotechnology's investors?

Vir Biotechnology's investors include GV, ARCH Venture Partners.

When was Vir Biotechnology founded?

Vir Biotechnology was founded in 2016.

Where is Vir Biotechnology headquartered?

Vir Biotechnology is headquartered in San Francisco, California, United States.

What industry is Vir Biotechnology in?

Vir Biotechnology operates in Biotech, Drug Discovery, Healthcare, Life Sciences.

How many employees does Vir Biotechnology have?

Vir Biotechnology has 201-500 employees.

Vir Biotechnology

IPO

Powering the Immune System to Transform Lives

Public · San Francisco, United States · Founded 2016 · $250.0M raised

Headquarters: San Francisco, California
Employees: 201–500
Founded: 2016
Business Model: B2B
Website: vir.bio

Total Funding: $250.0M
Last Round: $250.0M Growth EquityOct 2024
Rounds: 2
Type: Public

About

Vir Biotechnology is a clinical-stage immunology company leveraging the immune system to develop treatments for infectious diseases and cancer. Its pipeline is built on two core platforms: a next-generation antibody platform and the PRO-XTEN protease-releasable masking technology. Lead programs target chronic hepatitis delta, oncology, HIV, and other serious conditions with high unmet need.

Summary

Vir Biotechnology is a Biotech company based in San Francisco, United States, founded in 2016. It has raised $250.0M in total across 2 rounds, most recently a $250.0M Growth Equity round in Oct 2024. Investors include GV and ARCH Venture Partners.

LinkedIn X (Twitter)